Eccogene

About Eccogene

Eccogene is a clinical stage biopharmaceutical company focused on developing best-in-class small molecule therapeutics for cardiometabolic and inflammatory conditions. The company is dedicated to discovering safer and more effective oral therapies that can be used alone or in combination with GLP-1 receptor agonists to address conditions beyond weight management, aiming to improve care and expand access to cost-effective medicines for millions of patients worldwide.

Products & Services

ECC5004:A small molecule GLP-1 receptor agonist for metabolic diseases, licensed to AstraZeneca for global development and commercialization (except in China, where Eccogene co-develops and co-commercializes with AstraZeneca).

ECC4703:A THR-β agonist targeting metabolic diseases, currently in development.

ECC0509:An SSAO inhibitor for inflammatory and metabolic diseases, in clinical development.

Preclinical Programs:Programs targeting pathways such as amylin and GIP for metabolic conditions.

Specialties

Small molecule therapeutics Cardiometabolic diseases Inflammatory conditions GLP-1 receptor agonists Translational research Diabetes and weight management Drug discovery

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 25000000 MR: - FA: CNY 180 million (about $25 million) FAN: 25000000	D: 2023-06-11 FD: 2023-06-11	9 investors

Series B Latest

2023-06-11

$25.0M

9 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

Jingye Zhou

Co-founder & CEO

LinkedIn (Pro only)

J

Jianfeng Xu

Co-founder and Chief Scientific Officer

J

Jai Patel

Chief Medical Officer

T

Ting (Tim) Xiao

CFO

D

David Andrew D'Alessio

Lindquist Presidential Distinguished Chair Professor of Medicine and Chief, Division of Endocrinology and Metabolism

M

Mitchell A. Lazar

Willard and Rhoda Ware Professor in Diabetes and Metabolic Diseases

View 8 more team members with Pro

Unlock Full Team Directory

Recent News

Eccogene Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised